These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38807017)

  • 1. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 Jul; 19(4):635-644. PubMed ID: 38807017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
    Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
    Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
    Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
    Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
    N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
    Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
    Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
    Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
    Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
    Miyake M; Nishimura N; Oda Y; Miyamoto T; Ohmori C; Takamatsu N; Itami Y; Tachibana A; Matsumoto Y; Kiba K; Tomioka A; Yamamoto H; Okajima E; Masaomi K; Sakamoto K; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
    Jpn J Clin Oncol; 2024 Mar; 54(3):329-338. PubMed ID: 38061911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
    Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
    Minato A; Furubayashi N; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
    Clin Genitourin Cancer; 2024 Oct; 22(5):102148. PubMed ID: 39033710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab
    Minato A; Furubayashi N; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Nakamura M; Harada K; Fujimoto N
    Anticancer Res; 2024 Aug; 44(8):3419-3426. PubMed ID: 39060065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
    Hoffman-Censits J; Lombardo K; McConkey D; Hahn NM; Bashir B; Kelly WK; Johnson B; Matoso A
    Urol Oncol; 2021 Oct; 39(10):619-622. PubMed ID: 34148797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
    McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J
    Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.